Published on: March 14, 2025.
Certain breeds, such as Golden Retrievers, Boxers, and German Shepherds, have a higher susceptibility to HSA, suggesting a possible genetic basis for disease susceptibility. However, the exact molecular mechanisms underlying the predisposition of these breeds to hemangiosarcoma are not fully understood. A recent study aimed to deepen the understanding of HSA by re-analyzing publicly available RNA sequencing data from dogs, with a focus on Golden Retrievers. This research sought to identify differentially expressed genes (DEGs) and molecular biomarkers associated with HSA in the spleen, heart, and liver.
The analysis identified several genes, including ALB, TNNT2, VIM, and CA9, as potential biomarkers for HSA in Golden Retrievers. The ALB gene, which was downregulated in both splenic and hepatic HSA tissues, may play a role in regulating liver function during the disease. Transcription factors such as STAT3, TP53, PPARG, and ATF3, along with microRNAs like miR-21-5p, miR-92a-3p, and miR-155-5p, were also highlighted as potential biomarkers for hepatic HSA. Vimentin (VIM), a type III intermediate filament protein, emerged as a significant biomarker in specific histological variants of canine liver cancer, such as moderately differentiated hepatocellular carcinoma and mixed carcinoma. Additionally, 117 miRNAs and 43 transcription factors predicted to target the VIM gene were identified, many of which are linked to oncogenic processes.
The study also revealed breed-specific gene expression patterns in splenic HSA across six dog breeds, further emphasizing the genetic complexity of the disease. Among the findings, miR-214 was noted as a promising candidate for chemotherapeutic intervention in canine HSA. By uncovering these biomarkers and molecular pathways, the research provides critical insights into the mechanisms underlying HSA and highlights potential targets for early detection, diagnosis, and therapeutic strategies. This work represents a significant advancement in understanding and addressing this challenging cancer in dogs.
